Global Opioids Market Research Report 2017 - Top Manufacturers Pfizer Inc, Purdue Pharma, Sanofi, Boehringer Ingelheim, Actavis Plc

Researchmoz added Most up-to-date research on "Global Opioids Market Research Report 2017" to its huge collection of research reports.

In this report, the global Opioids market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Opioids in these regions, from 2012 to 2022 (forecast), covering
North America
Europe
China
Japan
Southeast Asia
India
Global Opioids market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Pfizer Inc
Purdue Pharma
Boehringer Ingelheim
Janssen Pharmaceuticals
Actavis Plc
Sanofi
Sun Pharmaceutical Industries Ltd
Mallinckrodt Pharmaceuticals
Endo Pharmaceuticals Inc
Egalet
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Morphine
Codeine
Methadone
Meperidine
Fentanyl
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Opioids for each application, including
Anesthesia
Cough Suppressant
Diarrhea suppressant

If you have any special requirements, please let us know and we will offer you the report as you want.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1197751

Table of Contents

Global Opioids Market Research Report 2017
1 Opioids Market Overview1.1 Product Overview and Scope of Opioids
1.2 Opioids Segment by Type (Product Category)
1.2.1 Global Opioids Production and CAGR (%) Comparison by Type (Product Category) (2012-2022)
1.2.2 Global Opioids Production Market Share by Type (Product Category) in 2016
1.2.3 Morphine
1.2.4 Codeine
1.2.5 Methadone
1.2.6 Meperidine
1.2.7 Fentanyl
1.3 Global Opioids Segment by Application
1.3.1 Opioids Consumption (Sales) Comparison by Application (2012-2022)
1.3.2 Anesthesia
1.3.3 Cough Suppressant
1.3.4 Diarrhea suppressant
1.4 Global Opioids Market by Region (2012-2022)
1.4.1 Global Opioids Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
1.4.2 North America Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 China Status and Prospect (2012-2022)
1.4.5 Japan Status and Prospect (2012-2022)
1.4.6 Southeast Asia Status and Prospect (2012-2022)
1.4.7 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Opioids (2012-2022)
1.5.1 Global Opioids Revenue Status and Outlook (2012-2022)
1.5.2 Global Opioids Capacity, Production Status and Outlook (2012-2022)

2 Global Opioids Market Competition by Manufacturers
2.1 Global Opioids Capacity, Production and Share by Manufacturers (2012-2017)
2.1.1 Global Opioids Capacity and Share by Manufacturers (2012-2017)
2.1.2 Global Opioids Production and Share by Manufacturers (2012-2017)
2.2 Global Opioids Revenue and Share by Manufacturers (2012-2017)
2.3 Global Opioids Average Price by Manufacturers (2012-2017)
2.4 Manufacturers Opioids Manufacturing Base Distribution, Sales Area and Product Type
2.5 Opioids Market Competitive Situation and Trends
2.5.1 Opioids Market Concentration Rate
2.5.2 Opioids Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Opioids Capacity, Production, Revenue (Value) by Region (2012-2017)
3.1 Global Opioids Capacity and Market Share by Region (2012-2017)
3.2 Global Opioids Production and Market Share by Region (2012-2017)
3.3 Global Opioids Revenue (Value) and Market Share by Region (2012-2017)
3.4 Global Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.5 North America Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.6 Europe Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.7 China Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.8 Japan Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.9 Southeast Asia Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.10 India Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Opioids Supply (Production), Consumption, Export, Import by Region (2012-2017)4.1 Global Opioids Consumption by Region (2012-2017)
4.2 North America Opioids Production, Consumption, Export, Import (2012-2017)
4.3 Europe Opioids Production, Consumption, Export, Import (2012-2017)
4.4 China Opioids Production, Consumption, Export, Import (2012-2017)
4.5 Japan Opioids Production, Consumption, Export, Import (2012-2017)
4.6 Southeast Asia Opioids Production, Consumption, Export, Import (2012-2017)
4.7 India Opioids Production, Consumption, Export, Import (2012-2017)

5 Global Opioids Production, Revenue (Value), Price Trend by Type
5.1 Global Opioids Production and Market Share by Type (2012-2017)
5.2 Global Opioids Revenue and Market Share by Type (2012-2017)
5.3 Global Opioids Price by Type (2012-2017)
5.4 Global Opioids Production Growth by Type (2012-2017)

6 Global Opioids Market Analysis by Application
6.1 Global Opioids Consumption and Market Share by Application (2012-2017)
6.2 Global Opioids Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

7 Global Opioids Manufacturers Profiles/Analysis
7.1 Pfizer Inc
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Opioids Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Pfizer Inc Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.1.4 Main Business/Business Overview
7.2 Purdue Pharma
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Opioids Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Purdue Pharma Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.2.4 Main Business/Business Overview
7.3 Boehringer Ingelheim
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Opioids Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Boehringer Ingelheim Opioids Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
7.3.4 Main Business/Business Overview

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=1197751

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market | New Release

Researchmoz added Most up-to-date research on "Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market" to its huge collection of research reports.

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

Summary

Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics. As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the exception of, for example, migraines, are heavily dominated by opioids. As a therapeutic drug class, opioids have virtually no competition from molecules with non-opioid receptor targets. However, although the competition is virtually exclusively limited to opioid compounds, the current environment within this therapeutic class is highly competitive and strongly diversified. The approved drugs are based on 16 different opioid compounds and are differentiated on a range of characteristics, which include dosage, route of administration and pharmacokinetic features, as well as increasingly on the basis of abuse-resistance technologies.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=158132

Whilst the prescription rates of opioid analgesic have seen a historically unprecedented increase over the last two decades, particularly in the US, this has resulted in a dramatic concomitant increase in opioid abuse and dependency. Over the last few years, the growing concern over opioid abuse has resulted in tighter regulations and increasingly vocal concerns by physicians. Due to these concerns from regulatory authorities and physicians about growing opioid abuse, there has been a seismic shift towards developing abuse-resistant formulations of extended-release opioid analgesics, including both novel products and reformulations of existing ones. Since the launch of the first abuse-resistant product, Embeda, in 2009, a whole range of novel products and reformulations of existing product ranges have been brought to the market. While abuse-resistant formulations do not confer any clinical benefits, they have become an essential differentiating factor in the current market environment in order ensure that products remain competitive for the future. There is a growing concentration and competition among abuse-resistant products, which is expected to be the primary driving factor in this largely stagnant market, particularly as the current developmental pipeline is very small and is characterized by a lack of innovation, with virtually no novel compounds and strong saturation across multiple pain indications.

Scope

- An overview of the current opioid product market.
- A brief discussion about the inconsistent prescription preferences among European physicians.
- A brief profile of the most important opioid products.
- A pipeline analysis of the opioid products currently in development and an overview of the developmental pipeline by phase, by the route of administration and a summary of the promising pipeline products. 
- An overview of the M&A and licensing deals, as well as co-development deals, across multiple indications in which opioids are frequently used in patients suffering from moderate to severe pain.

Reasons to buy

- Identify trends in the developmental pipeline for opioid analgesics.
- Develop their awareness of the regulatory environment, physician concerns and inconsistency of prescription preferences among physicians.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=158132